Reliance Global Group reports 2025 results, invests in cybersecurity

Reliance Global reported a FY2025 net loss of $7.0M versus a $9.1M loss in 2024, but shares have plunged ~84% over the past year to $0.26 (market cap ~$4.64M). Adjusted EBITDA was negative $1.6M in 2025 (vs -$0.3M in 2024), commission income fell 12% to $12.4M, and the company warns it is quickly burning through cash despite unrestricted cash rising to ~$1.3M from $0.4M. Strategically, Reliance completed a structured investment to pursue a 51% stake in Enquantum (pre-money valuation $2.04M) and signed a non-binding term sheet for Scentech Medical, signaling a pivot to scale tech assets under its new Scale51 model.

Analysis

The company’s pivot to build a platform by acquiring early-stage cybersecurity and AI assets creates a classic small-cap execution risk profile: outcomes are binary and tied to milestone-triggered earnouts and follow-on capital. That structure magnifies both dilution and operational execution risk because each acquisition converts product-development timelines into near-term financing events, making the equity behave more like a series of binary options than a stable operating business.

Second-order winners are infrastructure and tooling providers that scale deterministic compute and security stacks (outsourced hardware, cloud interconnects, test validation providers) — these capture recurring demand if the acquired IP proves commercial. Conversely, niche early-stage vendors and founders face increased disruption: they may now see lower acquisition pricing as these roll-ups seek cheap optionality, which compresses private-market exit values across the segment.

Near-term catalysts to watch are milestone confirmations, any announced financing/syndication, and progress against commercial pilots from the diagnostics/cyber assets — each can swing implied valuation sharply given illiquidity. Tail risks include rapid, repeated dilutive financings, failure to hit commercialization milestones (which would reset earnouts), and trading halts or microcap liquidity squeezes that amplify downside over days to weeks.

Given the asymmetric profile, the preferred portfolio posture is low-notional, event-driven exposure to the microcap (option-based hedged or short-limited structures) while overweighting public hardware/software names that benefit from secular AI/cyber demand. Execution should emphasize size discipline (small % NAV), clear stop rules, and horizon alignment with milestone timelines (3–12 months).

Key Decisions for Investors

• Initiate a small asymmetric short on RELIW (size 1–2% NAV): use a 3–6 month put spread to limit downside capital while retaining upside if a dilutive financing occurs. Target reward/risk ~3:1 — exit on clear milestone completion or if the stock rallies 25% from entry (stop).
• Event-driven hedge: allocate 0.5% NAV to a RELIW 3–6 month out-of-the-money put (or put spread) timed around the next financing/milestone update. This is a low-capital tail hedge against dilutive financing or failed earnouts; treat as binary insurance rather than a directional core position.
• Long SMCI via a 3–9 month call spread or outright equity (size 1–3% NAV): capitalize on secular AI/cyber infrastructure demand that benefits from any increase in compute deployments. Set profit-taking at 30–50% upside and a hard stop of 12–15% adverse move to preserve asymmetric payoff.
• Tactical long APP call spread (1–3 month): modest sized (0.5–1% NAV) bullish exposure to adtech/momentum if broader risk-on returns; use spreads to cap premium and aim for ~2:1 reward:risk. Close on signs of CPI/rate-driven ad contraction or if mobile advertiser KPIs roll over.
• Pair trade (defensive): long SMCI (1–2% NAV) financed by a small RELIW short (0.5–1% NAV) to capture secular hardware upside while neutralizing some market/directional risk tied to microcap volatility. Rebalance after each corporate milestone or any near-term follow-on financing announcement.